Home
Clinical Trials
Study of Zanzalintinib (XL092...

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Last Updated: 2025-08-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2/PHASE3

Total Enrollment

600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-06-07

Study Completion Date

2029-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with programmed death-ligand 1 (PD-L1) positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

NCT06912087

Head and Neck Neoplasms Carcinoma, Squamous Cell Neoplasm Recurrence, Local +3 more

RECRUITING PHASE1

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

NCT03468218

Metastatic Head and Neck Carcinoma Paranasal Sinus Squamous Cell Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma +21 more

ACTIVE_NOT_RECRUITING PHASE2

A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

NCT02358031

Recurrent Head and Neck Cancer Metastatic Head and Neck Cancer

COMPLETED PHASE3

Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer

NCT02777385

Head and Neck Squamous Cell Carcinoma

COMPLETED PHASE2

Pembrolizumab in HNSCC With Residual Disease After Radiation

NCT02892201

Head and Neck Squamous Cell Carcinoma

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Head and Neck Squamous Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Zanzalintinib + Pembrolizumab

Subjects with R/M HNSCC will receive zanzalintinib + pembrolizumab

Group Type EXPERIMENTAL